Ad
related to: small molecule vs large pharma list
Search results
Results From The WOW.Com Content Network
Small-molecule anti-genomic therapeutics, or SMAT, refers to a biodefense technology that targets DNA signatures found in many biological warfare agents. SMATs are new, broad-spectrum drugs that unify antibacterial, antiviral and anti-malarial activities into a single therapeutic that offers substantial cost benefits and logistic advantages for ...
Small molecule Multiple myeloma. Myelodysplastic syndromes. Celgene: 5,801 821 10 Sofosbuvir: Sovaldi Small molecule Hepatitis C: Gilead Sciences: 5,276 (5,007) 11 Fluticasone propionate/salmeterol: Seretide Advair Small molecule Asthma. Chronic obstructive pulmonary disease. GlaxoSmithKline: 5,227 (778) 12 Rosuvastatin: Crestor Small molecule ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
“Big Pharma CEOs and their army of lobbyists spared no expense to defend a system rigged in their favor, prioritizing profits and price gouging over people’s health.
Biosimilars require a different regulatory framework compared to small-molecule generics. Legislation in the 21st century has addressed this by recognizing an intermediate ground of testing for biosimilars. The filing pathway requires more testing than for small-molecule generics, but less testing than for registering completely new ...
Pages in category "Small-molecule drugs" The following 21 pages are in this category, out of 21 total. This list may not reflect recent changes. B. BIIB131;
Chimeric small molecule therapeutics are a class of drugs designed with multiple active domains to operate outside of the typical protein inhibition model. While most small molecule drugs inhibit target proteins by binding their active site, chimerics form protein-protein ternary structures to induce degradation or, less frequently, other protein modifications.
Unlike with generic drugs of the more common small-molecule type, biosimilar drugs generally exhibit high molecular complexity and may be quite sensitive to changes in manufacturing processes. Despite this heterogeneity, all biopharmaceuticals , including biosimilars, must maintain consistent quality and clinical performance throughout their ...